🇺🇸 Lidocaine/Magnesium in United States

54 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 54

Most-reported reactions

1. Drug Ineffective — 9 reports (16.67%)
2. Adverse Reaction — 7 reports (12.96%)
3. Nausea — 7 reports (12.96%)
4. Diarrhoea — 6 reports (11.11%)
5. Off Label Use — 6 reports (11.11%)
6. Fatigue — 5 reports (9.26%)
7. Pupillary Light Reflex Tests Abnormal — 4 reports (7.41%)
8. Vomiting — 4 reports (7.41%)
9. Arrhythmia — 3 reports (5.56%)
10. Blood Lactic Acid Increased — 3 reports (5.56%)

Source database →

Frequently asked questions

Is Lidocaine/Magnesium approved in United States?

Lidocaine/Magnesium does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Lidocaine/Magnesium in United States?

University of Wisconsin, Madison is the originator. The local marketing authorisation holder may differ — check the official source linked above.